Alvotech (ALVO) Non-Current Deferred Tax Liability (2020 - 2026)
Alvotech (ALVO) posted Non-Current Deferred Tax Liability of $7.2 million for Q1 2026, down 8.95% on a QoQ basis from $7.9 million in Q4 2025, and up 248.1% year-over-year from $2.1 million in Q1 2025.
Alvotech (ALVO) Non-Current Deferred Tax Liability (2020 - 2026) Analysis & Trends
Alvotech's Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at $7.2 million for Q1 2026.
- Quarterly Non-Current Deferred Tax Liability rose 248.1% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (up 248.1% YoY) and the FY2025 annual result came in at $7.9 million, up 334.46% from the prior year.
- Non-Current Deferred Tax Liability was $7.2 million for Q1 2026 at Alvotech, down from $7.9 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $7.9 million in Q4 2025 and bottomed at $45000.0 in Q2 2023.
- A 5-year average of $2.4 million and a median of $1.6 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability tumbled 82.85% — and 2024, when it soared 3316.98%.
- Alvotech's Non-Current Deferred Tax Liability stood at $309000.0 in 2022, then tumbled by 82.85% to $53000.0 in 2023, then surged by 3316.98% to $1.8 million in 2024, then surged by 334.46% to $7.9 million in 2025, then dropped by 8.95% to $7.2 million in 2026.
- Business Quant data shows ALVO's Non-Current Deferred Tax Liability at $7.2 million in Q1 2026, $7.9 million in Q4 2025, and $7.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alvotech | 935.87 Mn | 935.87 Mn | 5.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.16 Mn |
| Mar 31, 2026 | 7.16 Mn |
| Dec 31, 2025 | 7.87 Mn |
| Dec 31, 2025 | 7.87 Mn |
| Sep 30, 2025 | 7.54 Mn |
| Sep 30, 2025 | 7.54 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Mar 31, 2025 | 2.06 Mn |
| Mar 31, 2025 | 2.06 Mn |
| Dec 31, 2024 | 1.81 Mn |
| Dec 31, 2024 | 1.81 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 1.39 Mn |
| Jun 30, 2024 | 1.39 Mn |
| Mar 31, 2024 | 1.61 Mn |
| Mar 31, 2024 | 1.61 Mn |
| Dec 31, 2023 | 53,000.00 |
| Dec 31, 2023 | 53,000.00 |